Changes in Breast 3D Ultrasound Measurements Using Toremifene

Satakunta Central Hospital20 enrolled

Overview

To investigate if there are detectable changes in volume and circulation in breasts of healthy volunteers using toremifene 20 mg in luteal phase of the menstruation cycle versus nonmedicated cycle.

20 women were participated to this trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Circulatory; Change

Interventions

ToremifeneDRUG

20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer

Eligibility

Sex: FEMALEMin age: 25 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * age 25-45 healthy person * regular menstrual cycles * safe contraception(for example sterilization or condom) Exclusion Criteria: * gynecological or other type of cancer * hormonal contraception * pregnancy

Locations (1)

Porin Lääkäritalo

Pori, Finland

Outcomes

Primary Outcomes

circulation changes of the breast

Time frame: cycle day 23 to 26

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.